KCT0004125招募中未知
A dose-block randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of DW2008S after oral administration in healthy male subjects
Dongwha Pharmaceutical0 个研究点目标入组 64 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- Male
入选标准
- •1. A healthy male adult within the range of 19 to 45 years old at the time of screening
- •2. BMI=18.0~27.0kg/m2, one with weight range of 55kg to 90kg (BMI= kg/(m)2)
- •3. Subject should not have congenital/chronic disease or pathological symptoms/findings
- •4. Subject judged to be eligible by clinical tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol.
- •5. One who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol
排除标准
- •1. one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history
- •2. one with disorders of micturition include benign prostatic hyperplasia
- •3. one who is allergic or has clinically significant allergic history to drug(Aspirin, Antibiotics, etc.), and investigational product.
- •4. One who have indicated the AST or ALT values are 1.5 times higher than the normal range upper limit in screening test.
- •5. One who has included blood pressure in the vital signs measured in the seated position after a rest for 3 min or more, systolic pressure < 100 mmHg or >160 mmHg
- •6. One who has included blood pressure in the vital signs measured in the seated position after a rest for 3 min or more, diastolic pressure < 50 mmHg or >100 mmHg
- •7. One who has drug abuse history within 2 weeks prior to the first administration / One who is positive response in urine toxic screening for drug abuse
- •8.A person who takes prescription drug or Chinese medicine within 2 weeks before Investigational Product administration and who takes OTC or vitamins within 10 days before Investigational Product administration. (but, clinical study may be conducted when different conditions are appropriate depending on the PI’s opinion.)
- •9. A person who is currently participating in a clinical study or 6 months has not passed since the final administration of another clinical study.
- •10. Donation of a unit of blood within two months, or of blood components within one month, or receipt of blood transfusion within one month before the first administration of the study drug.
- •11. One who continue to drink alcohol (21 units/week over, 1 unit = 10g of pure alcohol) or stop drinking during the clinical study.
- •12. A smoker on average daily, over 10 cigarettes, in the past 3 months or stop smoking during the clinical study.
- •13. One who eats grapefruit/caffein products from 24 hours prior to hospitalization during study drug administration.
- •14. One who plan pregnancy or don't use reliable methods of birth-control(one's own and partner's sterilization operation, partner's contraceptive device, barrier contraception or combined using of condom)
- •15. Otherwise judged by the investigator to be inappropriate for inclusion in the study
研究者
相似试验
招募中
不适用
A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519 after oral administration in healthy adult volunteersDiseases of the circulatory systemKCT0001159Chong Kun Dang40
已完成
不适用
A dose-block randomized, double-blind, placebo-controlled, single dosing, dose-escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HNP-2006 after intravenous administration in healthy adult volunteersKCT0005257Hana Pharm40
尚未招募
不适用
A dose-block randomized, double-blind, placebo-controlled, single and multiple ascending dose, first-in-human, phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics after subcutaneous administration of C1K in healthy subjectsKCT0008074Ensol Biosciences35
招募中
不适用
A dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation clinical phase 1 trial to investigate the safety, tolerability, and pharmacokinetics of DWP09031 after oral administration in healthy male subjectsKCT0000343Inje University Busan Paik Hospital64
已完成
不适用
Phase 1 study for NASHKCT0005295J2H Biotech100